CELZ CELZ
Company Profile ↓Company Overview
CELZ (CELZ) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $6.00K (-45.5% YoY); net profit $-6.00M.
- Trailing 12 Months Year-on-year growth — revenue -45.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -48.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -48.43% |
| 1 Year: | -45.45% |
Stock Price Performance
| 1 Year: | -77.10% |
| 6 Months: | -66.56% |
| 3 Months: | -70.01% |
| 1 Month: | -38.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.65 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -48.4% CAGR over 5 years.
- Trading 88.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.60K | 4.80K | 52.40K | 50.80K | 61.60K | 57.50K | 42.10K | 27.90K | 77.00K | 0 | 10.00K | 10.00K | 15.00K | 0 | 55.00K | 0 | 0 | 6.00K | 0 | 8.00K | 0 | 3.00K | 0 | 0 | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 7.20K | 2.27K | 16.00K | 36.56K | 42.40K | 49.50K | 27.90K | 17.10K | 59.40K | 0 | 5.50K | 6.00K | 8.21K | 0 | 39.00K | 0 | 0 | 3.60K | 0 | 4.80K | 0 | 1.80K | 0 | 0 | 0 |
| Operating Income | -8.45K | -3.99K | -3.60K | -8.04K | -3.63K | -3.55K | -6.99K | -3.77K | -3.73K | -147.84K | -209.25K | -212.54K | -240.85K | -395.99K | -295.00K | -204.22K | -314.83K | -274.83K | -250.70K | -275.46K | -273.42K | -335.04K | -214.26K | -242.47K | -303.94K | -515.84K | -833.44K | -1.15M | -1.79M | -1.02M | -1.11M | -1.19M | -1.54M | -1.12M | -1.63M | -1.11M | -1.66M | -1.26M | -1.27M | -1.46M |
| Net Income | -10.05K | -5.74K | -5.44K | -10.02K | -5.74K | -5.75K | -9.27K | -6.27K | -6.30K | -147.84K | -209.25K | -214.51K | -243.35K | -886.36K | -52.18K | -7.59M | -6.43M | -1.57M | -797.37K | -88.23K | -2.41M | 3.74M | -1.84M | 394.85K | 27.84M | -2.91M | -1.84M | -1.15M | -1.79M | -982.34K | -1.05M | -1.10M | -1.45M | -1.04M | -1.56M | -1.04M | -1.64M | -1.23M | -1.24M | -1.41M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.12 | -0.01 | 0.00 | 0.00 | -0.01 | 0.14 | 11.18 | -1.25 | -0.75 | -0.18 | -0.20 | -0.07 | - | - | - | 0.73 | -1.11 | -0.75 | -0.83 | -0.48 | -0.48 | -0.38 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 4.36K | 18.03K | 45.17K | 59.83K | 25.19K | 87.73K | 3.20K | 4.20K | 2.88K | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 59.18K | 10.00K | 659.70K | 230.94K | 319.03K | 309.48K | 992.72K | 422.39K | 924.75K | 581.80K | 743.30K | 501.26K | 465.15K | 541.66K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.80K | 124.40K | 165.50K | 164.50K | 87.75K | 88.60K | 9.00K | 11.00K | 6.00K |
| Gross Profit | - | - | - | - | - | - | 0 | -3.20K | 54.02K | 120.00K | 113.90K | 39.80K | 60.11K | 5.40K | 6.60K | 3.81K |
| Operating Income | -14.29K | -19.83K | -20.10K | -20.12K | -19.43K | -20.83K | -759.67K | -1.18M | -1.11M | -1.13M | -1.11M | -3.13M | -10.24M | -5.62M | -5.74M | -6.14M |
| Net Income | -17.26K | -24.05K | -25.59K | -27.28K | -28.01K | -30.76K | -766.07K | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M | -6.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -62.69 | 5.61 | -0.93 | -3.76 | -3.71 | -2.52 |
| R&D Expense | - | - | - | - | - | - | 85.33K | 260.08K | 96.62K | 0 | 0 | 109.18K | 6.27M | 1.97M | 2.40M | 2.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 414 | 3.10K | 1.57K | 374 | 954 | 49.60K | 322.51K | 203.15K | 477.16K | 530.80K | 717.77K | 11.27M | 19.19M | 10.72M | 6.67M | 7.81M |
| Total Equity | - | -48.11K | -72.16K | -97.75K | -125.03K | -153.04K | 49.50K | -157.79K | -2.24M | -3.99M | -8.07M | -39.80M | 10.22M | 15.86M | 10.34M | 6.34M | 7.51M |
| Cash & Equivalents | 575 | 414 | 1.10K | 781 | 374 | 954 | 100 | 221.87K | 13.70K | 304.06K | 88.65K | 98.01K | 10.72M | - | - | - | - |
| Long Term Debt | - | - | - | - | - | - | - | - | 493.25K | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | 100 | 480.30K | 2.44M | 4.47M | 8.60M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K | 284.88K |
| Current Liabilities | - | 48.52K | 75.27K | 99.32K | 125.41K | 154.00K | 100 | 453.86K | 2.44M | 4.47M | 8.60M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K | 284.88K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.66K | -13.96K | -16.77K | -22.91K | -17.32K | -14.64K | -445.23K | -889.62K | -1.05M | -1.21M | -434.56K | -2.22M | -7.80M | -8.03M | -5.30M | -5.86M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | -10.00K | 0 | - | 0 | -250.00K | 0 | -10.08M | 3.45M | 6.32M | -50.50K |
| Financing Cash Flow | 13.50K | 14.65K | 16.45K | 22.50K | 17.90K | 13.90K | 677.00K | 681.45K | 1.34M | 997.68K | 693.92K | 12.84M | 15.47M | -270.95K | 1.45M | 7.17M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 270.95K | 174.96K | 10.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | -66.7% | 43.4% | 72.5% | 69.2% | 45.4% | 67.8% | 60.0% | 60.0% | 63.4% |
| Operating Margin % | - | - | - | - | - | - | - | -24,537.6% | -895.7% | -682.9% | -677.7% | -3,562.2% | -11,562.5% | -62,445.9% | -52,216.9% | -102,380.2% |
| Net Margin % | - | - | - | - | - | - | - | -55,398.1% | -10,977.2% | -5,126.1% | -22,082.2% | 21,892.8% | -11,449.3% | -58,739.7% | -49,940.7% | -99,916.8% |
| ROE % | 35.9% | 33.3% | 26.2% | 21.8% | 18.3% | -62.1% | 485.5% | 118.9% | 341.8% | 105.1% | 91.3% | 188.0% | -63.9% | -51.1% | -86.6% | -79.8% |
| ROCE % | 29.7% | 27.5% | 20.6% | 16.1% | 12.7% | -42.1% | 578.3% | 52.8% | 27.9% | 14.0% | 2.8% | -30.6% | -64.6% | -54.3% | -90.6% | -81.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. SEC Filing (Aug 3, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxORnVWVmRacExqcmtIMFFPNVROOG9qdlpfaW1nZk9lSmlSOU5TTkVkZWU4T3pMeUxCT1pPUDM2Nlp2RndsWllYRjlrSllHWjNZM2g0VlVmNktZWXF4REZWZDRUd1BJUjh4S0NrTUdYbjBDazJPdjgzb1J5WElGdXpXNFJOdWNMenpMaW1nZX…
CELZ Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBQdjZKbVpuVU91bFZpa1BaT05PZzFJdFNENzljQk9NbVlYVkx2cUkzY0ZOU1NJNWoxNDBHa1BGSDNxMnhoSi1KalRxSXFmb2xPSjdkUlBHVlFiSnRUc2o0TGo1S09hMXlGc2tzOEtuRWxPeHlvR2F6dlV3?oc=5" target="_blank">CEL…
Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQTElwYTlpVVFTRVhmUkpxZDh0RUdUcUd3RnJwOEx3c0MtUml1ZkVSdktpcktqaFdja1pNS0RaaWxLaUtzVmw4RFJaUGdsaHJZWWQtWFNpTFREVThjcDB4NUdGUVV0WjlxcjVlSUE0YkNOSHFZNnRJUjBFOGZlb1d3Z3Brb1MzdXlmaFU5T1…
CELZ Stock Jumps As FDA Clears Expanded Pain Trial - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNX3VwRTEySUNMS19IWU5SX1NCZGdRc2lfeUk2aUpOaGtMMVJyeWlHVVduNGtsWXNOODZqQzVDbkpVT3VDdHdVNkpvbVUzbzVOQnUwNl95UE9tLUJybnU4OU5oVm1CQTFzUVcwMXUzSlhYRVREa2FTOFlwc2NvNFJHVGl4VVU2RVhxMnEwUj…
Market Movers | Winners: IVF, LVWR, ARL | Losers: CELZ, TVRD, KUST - Trefis
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNZ3N0R2lGU0QxNDctU1VZLWRSekFqMVM4ZUxXOWpzOUx1QkhGZFZzby1pc2ozOElOUWNMSUw2c2dSYVFUM0JKX0pGZ1A4TXZYTHNadG8wMFJSTktSaXFOeTFiVTBEWDV3ZE9SYjVqODdVRmxhUkZyUjFSVTdfWlByb1JFNzk4NHl2YXQyRE…
When Will Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Become Profitable? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxQS3U5UGhGeGJxakN6WHNSOGIxZDJsLVNGbHlYUkEteHZvdmZ4Uk8yNVh1TTBZeHZoakZuRFVubkxKUW1ScTE0eHZEWXdBWDRYbUY0aTBJbHNMUXpTMnA3REJBRGpiUDN5bkluR2Z0TjZuWGJBRFdQak5EU0gzaDVxYThuRlFNdE1oeC1JSm…
CELZ — Frequently Asked Questions
What is the current share price of CELZ?
As of 2026-08-05 17:25 PDT, CELZ trades at $0.67 on NASDAQ/NYSE. Its 52-week range is $0.65 to $5.59.
What is the P/E ratio of CELZ?
CELZ trades at a trailing price-to-earnings (P/E) ratio of -0.27.
What is the return on equity (ROE) of CELZ?
CELZ has a return on equity (ROE) of -79.78%. Its return on capital employed (ROCE) is -81.64%.
Is CELZ a good stock to buy?
This page provides a data-driven analysis of CELZ, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.